Oncogene
This journal aims to make substantial advances in our knowledge of processes that contribute to cancer by publishing outstanding research.
The realization of direct-acting agents targeting the MYC oncogene has been a long-standing challenge in cancer therapeutics. Our recent paper describes new antisense tools with potent anti-MYC effects.
EGF-SNX3-EGFR axis drives tumor progression and metastasis in triple-negative breast cancers
Sorting Nexin 3 (SNX3), a member of the recycling retromer complex, is a critical player in the epidermal growth factor (EGF) stimulated EGFR network in triple-negative breast cancers.
A negative NKX2-1/DUSP6/ERK signal inhibits lung cancer
Lung cancer is the #1 cancer killer in the U.S. Lung cancer’s heterogenous pathology and complicated oncogenic signaling networks have impeded care.
Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth
We show the importance of hypoxia in activating enzymes that control proper collagen maturation in eye melanoma. Disrupting this process with an inhibitor of the HIF-1/p300 transcription complex leads to disordered collagen structure and reduces tumor growth in the eye and liver in mice xenografts.